Arcutis Biotherapeutics posts strong Q3 revenue and lifts FY 2026 guidance

Arcutis Biotherapeutics reported third‑quarter net product revenue of $143.9 million, a 45% year‑over‑year increase, driven by growth across its ZORYVE franchise. GAAP earnings were $0.06 per share and net income was $8.8 million. The company raised its full‑year 2026 revenue guidance to a range of $535 million‑$545 million. Management highlighted a cash balance of $259.8 million, debt of $109.4 million, and a 60% rise in SG&A expenses to $99.6 million as it expands its sales force and marketing campaigns.

The higher guidance signals a larger revenue runway for investors, potentially supporting a higher valuation. The raised outlook also reflects stronger commercial execution, which may improve cash flow expectations for the remainder of the year.

  • 1Total net product revenue was $143.9 million, up 45% year‑over‑year.
  • 2GAAP earnings per share were $0.06 for the quarter.
  • 3Net income was $8.8 million, or $0.07 per basic share.
  • 4Full‑year 2026 revenue guidance was raised to $535 million‑$545 million.
  • 5Cash and marketable securities totaled $259.8 million as of September 30, 2026.
  • 6Total debt was $109.4 million at quarter end.

Sources